Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 122, Issue 4, Pages 1205-1208Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI62972
Keywords
-
Categories
Funding
- NHLBI NIH HHS [R01HL098032, R01HL096973, P01HL103455, R37 HL058091, P01 HL103455, R01 HL098032, R01 HL096973] Funding Source: Medline
Ask authors/readers for more resources
Blood transfusion represents the first and most prescribed cell-based therapy; however, clinical safety and efficacy trials are lacking. Clinical cohort studies have suggested that massive transfusion and/or transfusion of aged stored blood may contribute to multiorgan dysfunction in susceptible patients. In this issue of the JCI, Baek and colleagues report that aged stored blood hemolyzes after massive transfusion in a guinea pig model. Hemolysis led to vascular and kidney injury that was mediated by cell-free plasma hemoglobin and prevented by coinfusion of the specific hemoglobin scavenger protein, haptoglobin. These studies support an expanding body of research indicating that intravascular hemolysis is a pathological mechanism in several human diseases, including multiorgan dysfunction after either massive red blood cell transfusion or hemoglobin-based blood substitute therapy, the hemoglobinopathies, malaria, and other acquired and genetic hemolytic conditions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available